121 related articles for article (PubMed ID: 9116068)
1. Survival and the use and costs of hospital services for London AIDS patients treated with AZT.
Beck EJ; Kupek EJ; Petrou S; Wadsworth J; Miller DL; Pinching AJ; Harris JA
Int J STD AIDS; 1996; 7(7):507-12. PubMed ID: 9116068
[TBL] [Abstract][Full Text] [Related]
2. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989.
Beck EJ; Kennelly J; McKevitt C; Whitaker L; Wadsworth J; Miller DL; Easmon C; Pinching AJ; Harris JR
AIDS; 1994 Mar; 8(3):367-77. PubMed ID: 8031516
[TBL] [Abstract][Full Text] [Related]
3. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre.
Beck EJ; Whitaker L; Kennelly J; McKevitt C; Wadsworth J; Miller DL; Easmon C; Pinching AJ; Harris JR
AIDS; 1994 Mar; 8(3):379-84. PubMed ID: 8031517
[TBL] [Abstract][Full Text] [Related]
4. The use and cost of hospital services by London AIDS patients with different AIDS defining conditions.
Beck EJ; Kupek EJ; Wadsworth J; Miller DL; Pinching AJ; Harris JR
J Public Health Med; 1996 Dec; 18(4):457-64. PubMed ID: 9023806
[TBL] [Abstract][Full Text] [Related]
5. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months.
Scitovsky AA; Cline MW; Abrams DI
J Acquir Immune Defic Syndr (1988); 1990; 3(9):904-12. PubMed ID: 2384866
[TBL] [Abstract][Full Text] [Related]
6. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers.
Ramsey SD; Nettleman MD
Med Decis Making; 1992; 12(2):142-8. PubMed ID: 1573981
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection.
Cox PH; Martin MA; Styer CM; Beall GN
Nurse Pract; 1990 May; 15(5):36, 39-44. PubMed ID: 2342666
[TBL] [Abstract][Full Text] [Related]
9. Forecasting the personal medical care costs of AIDS from 1988 through 1991.
Hellinger FJ
Public Health Rep; 1988; 103(3):309-19. PubMed ID: 2836880
[TBL] [Abstract][Full Text] [Related]
10. Demograghic and socio-economic determinants of community and hospital services costs for people with HIV/AIDS in London.
Kupek E; Dooley M; Whitaker L; Petrou S; Renton A
Soc Sci Med; 1999 May; 48(10):1433-40. PubMed ID: 10369442
[TBL] [Abstract][Full Text] [Related]
11. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons.
Stein MD; Piette J; Mor V; Wachtel TJ; Fleishman J; Mayer KH; Carpenter CC
J Gen Intern Med; 1991; 6(1):35-40. PubMed ID: 1999744
[TBL] [Abstract][Full Text] [Related]
12. The acquired immune deficiency syndrome and epidemic of infection with human immunodeficiency virus: costs of care and prevention in an inner London district.
Johnson AM; Adler MW; Crown JM
Br Med J (Clin Res Ed); 1986 Aug; 293(6545):489-92. PubMed ID: 3091176
[TBL] [Abstract][Full Text] [Related]
13. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.
Beck EJ; Tolley K; Power A; Mandalia S; Rutter P; Izumi J; Beecham J; Gray A; Barlow D; Easterbrook P; Fisher M; Innes J; Kinghorn G; Mandel B; Pozniak A; Tang A; Tomlinson D; Williams I
Pharmacoeconomics; 1998 Dec; 14(6):639-52. PubMed ID: 10346416
[TBL] [Abstract][Full Text] [Related]
14. Who found AZT works for AIDS?
Palca J
Science; 1991 Mar; 251(5001):1554. PubMed ID: 2011732
[No Abstract] [Full Text] [Related]
15. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
[TBL] [Abstract][Full Text] [Related]
16. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
Ayele T; Jarso H; Mamo G
AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
[TBL] [Abstract][Full Text] [Related]
17. [Direct costs of the treatment of AIDS in Mexico].
Tapia-Conyer R; Sepúlveda J; de la Rosa-Montaño BM; Revuelta-Herrera A
Salud Publica Mex; 1992; 34(4):371-7. PubMed ID: 1502657
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients.
De Simone C; Ferrazzi M; Bitonti F; Falciano M; Tzantzoglou S; Delia S; Sorice F
Immunopharmacol Immunotoxicol; 1988; 10(4):437-41. PubMed ID: 2469710
[TBL] [Abstract][Full Text] [Related]
19. Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department.
Nageswaran A; Kinghorn GR; Shen RN; Priestley CJ; Kyi TT
Int J STD AIDS; 1995; 6(5):336-44. PubMed ID: 8547414
[TBL] [Abstract][Full Text] [Related]
20. Survival and treatment of AIDS patients 1984-1993: experience of a smaller east London HIV centre.
Hillman RJ; Beck EJ; Mandalia S; Satterthwaite H; Rogers PA; Forster GE; Goh BT
Genitourin Med; 1997 Feb; 73(1):44-8. PubMed ID: 9155555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
